Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00871559 | A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies | PHASE1 | COMPLETED | 83 | — | — | Jun 1, 2009 | Feb 1, 2014 | Mar 26, 2014 | 8 | United States |
| Arm | Type | Description |
|---|---|---|
| Q2W | EXPERIMENTAL | REGN421 (SAR153192) taken once every two weeks (Q2W) |
| Name | Type | Description |
|---|---|---|
| REGN421(SAR153192) | DRUG | - |
Inclusion Criteria: 1. Male or female 18 years of age or older 2. Histologically diagnosis of advanced solid malignancy, with no standard therapeutic options of proven benefit. 3. Patients with measurable or non-measurable disease 4. At least 6 weeks must have elapsed since the last dose of bevaciz...